[{"id":"7ef4af00-eb0b-4c60-9128-d93df5188777","acronym":"","url":"https://clinicaltrials.gov/study/NCT04214392","created_at":"2021-01-18T20:31:17.890Z","updated_at":"2024-07-02T16:35:14.015Z","phase":"Phase 1","brief_title":"Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma","source_id_and_acronym":"NCT04214392","lead_sponsor":"City of Hope Medical Center","biomarkers":" MMP2","pipe":" | ","alterations":" MMP2-H","tags":["MMP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MMP2-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CHM 1101"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/26/2020","start_date":" 02/26/2020","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2024-03-19"},{"id":"d38762bf-65e1-4303-a1ad-8c58d324245c","acronym":"MM-Predict","url":"https://clinicaltrials.gov/study/NCT03526822","created_at":"2021-01-18T17:22:12.875Z","updated_at":"2024-07-02T16:35:16.448Z","phase":"","brief_title":"Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features.","source_id_and_acronym":"NCT03526822 - MM-Predict","lead_sponsor":"Assistance Publique Hopitaux De Marseille","biomarkers":" MMP2 • MMP9","pipe":"","alterations":" ","tags":["MMP2 • MMP9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/02/2018","start_date":" 07/02/2018","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-03-05"},{"id":"e86d670d-ff10-4e93-b7c9-1b7a0035cc36","acronym":"","url":"https://clinicaltrials.gov/study/NCT06230965","created_at":"2024-01-30T20:21:16.537Z","updated_at":"2024-07-02T16:35:21.824Z","phase":"","brief_title":"Clinical Study of Lung Protective Ventilation Strategies and Tumor Microenvironment","source_id_and_acronym":"NCT06230965","lead_sponsor":"Affiliated Hospital of Nantong University","biomarkers":" VEGFA • IL6 • TNFA • JAK1 • STAT3 • MMP2 • MMP9","pipe":"","alterations":" ","tags":["VEGFA • IL6 • TNFA • JAK1 • STAT3 • MMP2 • MMP9"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 60","initiation":"Initiation: 02/15/2024","start_date":" 02/15/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-30"},{"id":"c3b4433b-bed2-433c-ac5b-3eebb0048cd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05627323","created_at":"2022-11-25T15:58:16.470Z","updated_at":"2024-07-02T16:35:29.405Z","phase":"Phase 1","brief_title":"CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma","source_id_and_acronym":"NCT05627323","lead_sponsor":"Chimeric Therapeutics","biomarkers":" MMP2","pipe":" | ","alterations":" IDH wild-type","tags":["MMP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CHM 1101"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 06/06/2023","start_date":" 06/06/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 01/01/2041","study_completion_date":" 01/01/2041","last_update_posted":"2023-11-13"},{"id":"3f0eee4c-cc3f-47e5-8775-fa046060ec8c","acronym":"EPMLARF","url":"https://clinicaltrials.gov/study/NCT04081805","created_at":"2023-09-14T17:11:53.239Z","updated_at":"2024-07-02T16:35:36.920Z","phase":"","brief_title":"LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2)","source_id_and_acronym":"NCT04081805 - EPMLARF","lead_sponsor":"Federal University of São Paulo","biomarkers":" MMP2 • MMP9 • MMP1 • MMP3","pipe":" | ","alterations":" VEGFA expression","tags":["MMP2 • MMP9 • MMP1 • MMP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VEGFA expression"],"overall_status":"Recruiting","enrollment":" Enrollment 195","initiation":"Initiation: 09/30/2019","start_date":" 09/30/2019","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2023-09-14"},{"id":"fdecd21b-0fab-4b1e-b324-36eed6535262","acronym":"","url":"https://clinicaltrials.gov/study/NCT01493219","created_at":"2021-01-18T06:15:14.989Z","updated_at":"2024-07-02T16:35:37.041Z","phase":"","brief_title":"Biomarkers for Prognosis of Glioblastoma (GBM)","source_id_and_acronym":"NCT01493219","lead_sponsor":"University of Nebraska","biomarkers":" MMP2 • MMP9","pipe":"","alterations":" ","tags":["MMP2 • MMP9"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 09/20/2011","start_date":" 09/20/2011","primary_txt":" Primary completion: 09/01/2017","primary_completion_date":" 09/01/2017","study_txt":" Completion: 09/01/2017","study_completion_date":" 09/01/2017","last_update_posted":"2023-09-14"},{"id":"68aa0036-1540-4538-858b-bf876fa2e9ec","acronym":"RACING","url":"https://clinicaltrials.gov/study/NCT03745430","created_at":"2021-01-18T18:20:40.965Z","updated_at":"2025-02-25T14:27:50.093Z","phase":"Phase 1/2","brief_title":"RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT03745430 - RACING","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" PTEN • FLT1 • SPARC • THBS1 • EREG • MMP2 • VEGFB • MMP9","pipe":" | ","alterations":" EGFR mutation • PTEN mutation","tags":["PTEN • FLT1 • SPARC • THBS1 • EREG • MMP2 • VEGFB • MMP9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • Cyramza (ramucirumab)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 01/29/2019","start_date":" 01/29/2019","primary_txt":" Primary completion: 06/17/2022","primary_completion_date":" 06/17/2022","study_txt":" Completion: 04/23/2023","study_completion_date":" 04/23/2023","last_update_posted":"2023-05-24"},{"id":"133ce981-1de7-4e20-8506-f027764c0621","acronym":"","url":"https://clinicaltrials.gov/study/NCT04097067","created_at":"2021-12-02T22:53:53.888Z","updated_at":"2024-07-02T16:35:47.704Z","phase":"Phase 2","brief_title":"ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma","source_id_and_acronym":"NCT04097067","lead_sponsor":"University Hospital Muenster","biomarkers":" TNFA • MMP2","pipe":"","alterations":" ","tags":["TNFA • MMP2"],"overall_status":"Recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2023-05-17"},{"id":"0c90cd30-d9b5-4626-af27-72cee25782de","acronym":"REBORN","url":"https://clinicaltrials.gov/study/NCT04464122","created_at":"2021-01-18T21:27:30.836Z","updated_at":"2024-07-02T16:36:00.020Z","phase":"","brief_title":"Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)","source_id_and_acronym":"NCT04464122 - REBORN","lead_sponsor":"University of Roma La Sapienza","biomarkers":" KDR • IL6 • HIF1A • CXCL10 • FLT1 • CXCL9 • MMP2 • TIMP1 • VEGFC • CCL2 • TIMP2 • MMP9 • CXCL6 • FGF1 • IL1B • CHGA • CXCL1 • MMP14 • TIMP3","pipe":"","alterations":" ","tags":["KDR • IL6 • HIF1A • CXCL10 • FLT1 • CXCL9 • MMP2 • TIMP1 • VEGFC • CCL2 • TIMP2 • MMP9 • CXCL6 • FGF1 • IL1B • CHGA • CXCL1 • MMP14 • TIMP3"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 09/14/2024","primary_completion_date":" 09/14/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-11-23"},{"id":"0778f69f-9b26-4fa2-8d42-2591932eddd2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05560035","created_at":"2022-09-29T15:56:59.742Z","updated_at":"2024-07-02T16:36:03.186Z","phase":"","brief_title":"The Effect of Intravenous Lidocaine on THBS2 and Angiogenic Factors Expression in Women Undergoing Cervical Cancer Surgery","source_id_and_acronym":"NCT05560035","lead_sponsor":"General Hospital of Ningxia Medical University","biomarkers":" MMP2 • VEGFC • MMP9 • THBS2","pipe":"","alterations":" ","tags":["MMP2 • VEGFC • MMP9 • THBS2"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-09-29"},{"id":"4a4c81c9-5835-4629-9895-b12b1d7c0829","acronym":"","url":"https://clinicaltrials.gov/study/NCT03185039","created_at":"2021-01-18T15:42:20.679Z","updated_at":"2025-02-25T16:31:12.075Z","phase":"","brief_title":"Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents","source_id_and_acronym":"NCT03185039","lead_sponsor":"Institut Paoli-Calmettes","biomarkers":" MMP2 • MMP9","pipe":"","alterations":" ","tags":["MMP2 • MMP9"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/29/2017","start_date":" 05/29/2017","primary_txt":" Primary completion: 12/13/2022","primary_completion_date":" 12/13/2022","study_txt":" Completion: 12/13/2022","study_completion_date":" 12/13/2022","last_update_posted":"2020-01-10"}]